Search

Displaying results 3351 - 3360 of 4859 in total
  1. Drug

    Lasalocid

    go.drugbank.com/drugs/DB11423
    ExperimentalVet approved

    It is produced by strains of _Streptomyces lasaliensis_.

  2. Drug

    MORAb-066

    go.drugbank.com/drugs/DB17347
    Investigational

    It is being investigated in pancreatic cancer.

  3. Drug

    Chlorproguanil

    go.drugbank.com/drugs/DB12314
    Investigational

    It is a dichloro-derivative of chloroguanide.

  4. Drug

    Etofenamate

    go.drugbank.com/drugs/DB08984
    Investigational

    It is a non-steroidal anti-inflammatory drug (NSAID).

  5. Drug

    Magnesium orotate

    go.drugbank.com/drugs/DB13786
    Experimental

    It also exhibits antioxidant properties, since it is a key intermediate in the biosynthetic pathway of pyrimidines that promotes the synthesis of enzymes which act as free radical scavengers. … It is a source of magnesium and is used as a mineral supplement to treat Mg deficiency. Orotic acid acts as a transporter that carries magnesium into the cells.

  6. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths and insufficient evidence of clinical benefit during confirmatory trials [L941]. … It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) [L941].

  7. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    It is known by the standardized identifier NG2-73.

  8. Drug

    Sparsomycin

    go.drugbank.com/drugs/DB04222
    Experimental

    It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]

  9. Drug

    Nordazepam

    go.drugbank.com/drugs/DB14028
    Investigational

    It may have actions similar to those of diazepam.

  10. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain o...